Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of navtemadlin maintenance therapy in TP53 wild-type advanced or recurrent endometrial cancer
MOH_2023-10-02_012582Phase 3Not yet recruiting
- Sponsor
- Kartos Therapeutics
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endometrial cancer (EC) comparing Navtemadlin phase 3 dose with Matching placebo (2 arms). Planned start Sep 2023; status: not yet recruiting.
02
Drugs
navtemadlin
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on MOH_2023-10-02_012582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-10-02_012582.